Estimation of cardiotoxicity of epirubicin-cisplatin by determination of myoglobin.
Serum myoglobin was determined in 29 patients during a total of 46 cycles of treatment with epirubicin-cisplatin. Statistical evaluation showed highly significant correlations between the myoglobin values and the age of the patients and the cumulative dose of the cytostatic agents applied.
Lechner
W
W
Reider
W
W
Hetzel
H
H
Daxenbichler
G
G
Marth
C
C
D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006331:Heart Diseases / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D009211:Myoglobin / Q000097:blood*
D009211:Myoglobin; D015251:Epirubicin; D004317:Doxorubicin; D002945:Cisplatin